Predictors of outcome of reperfusion therapy.

The physician wishing to estimate the risk of death for a patient experiencing acute myocardial infarction can rapidly use parameters available on first seeing the patient to estimate the expected mortality and can update this risk during the early phase of the event. From the initial evaluation, factors that exclude patients from reperfusion therapy constitute a substantially elevated risk. Older age, haemodynamic distress, and markers of ongoing ischaemia provide a large amount of prognostic information from the initial exam. Careful surveillance for additional complications allows continuous risk assessment during the early course.

[1]  R. D'Agostino,et al.  Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic Predictive Instrument (TPI) Project results. , 1994, Circulation.

[2]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[3]  G. Breithardt,et al.  Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. , 1991, European heart journal.

[4]  R. Califf,et al.  Effect of Cigarette Smoking on Outcome After Thrombolytic Therapy for Myocardial Infarction , 1991 .

[5]  R. Califf,et al.  Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. The TAMI Study Groups. , 1989, Circulation.

[6]  P. Kudenchuk,et al.  Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). , 1993, The American journal of cardiology.

[7]  T. Killip,et al.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. , 1967, The American journal of cardiology.

[8]  U. Goldbourt,et al.  Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction , 1993 .

[9]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[10]  P. Grande,et al.  Estimation of Acute Myocardial Infarct Size in Man by Serum CK‐MB Measurements , 1982, Circulation.

[11]  R. Reneman,et al.  Complete recovery in plasma of enzymes lost from the heart after permanent coronary artery occlusion in the dog. , 1990, Circulation.

[12]  K. Swedberg,et al.  Vectorcardiographic monitoring to assess early vessel patency after reperfusion therapy for acute myocardial infarction. , 1995, European heart journal.

[13]  H. Hod,et al.  Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. , 1990, British heart journal.

[14]  E. Negri,et al.  Determinants of 6‐Month Mortality in Survivors of Myocardial Infarction After Thrombolysis Results of the GISSI‐2 Data Base , 1993, Circulation.

[15]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[16]  R. Califf,et al.  Racial Differences in Responses to Thrombolytic Therapy With Recombinant Tissue‐Type Plasminogen Activator: Increased Fibrin(ogen)olysis in Blacks , 1991, Circulation.

[17]  E. Topol,et al.  Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. , 1988, American heart journal.

[18]  C. Peterson A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: Grines CL, Browne KF, Marco J, et al. N Engl J Med 328:673–679 Mar 1993 , 1993 .

[19]  K Wegscheider,et al.  Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. , 1995, Journal of the American College of Cardiology.

[20]  M. Pfisterer,et al.  Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy. , 1996, European heart journal.

[21]  J. Herlitz,et al.  Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. , 1994, European heart journal.

[22]  J. Goldberg,et al.  Psychosocial influences on mortality after myocardial infarction. , 1984, The New England journal of medicine.

[23]  J E Keil,et al.  Socioeconomic factors and cardiovascular disease: a review of the literature. , 1993, Circulation.

[24]  M. Krucoff,et al.  Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. , 1986, The American journal of cardiology.

[25]  S. Chierchia,et al.  Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy. , 1987, The New England journal of medicine.

[26]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[27]  R B D'Agostino,et al.  A Time-Insensitive Predictive Instrument for Acute Myocardial Infarction Mortality: A Multicenter Study , 1991, Medical care.

[28]  R. Califf,et al.  Outcome of Patients Sustaining Acute Ischemic Mitral Regurgitation during Myocardial Infarction , 1992, Annals of Internal Medicine.

[29]  R. Califf,et al.  Individual risk assessment for intracranial haemorrhage during thrombolytic therapy , 1993, The Lancet.

[30]  R. Califf,et al.  Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. , 1984, The American journal of medicine.

[31]  R. Diaz,et al.  Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial , 1993, Circulation.

[32]  G. Tognoni,et al.  Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). , 1989, The American journal of cardiology.

[33]  R. Ideker,et al.  Comparison of enzymatic and anatomic estimates of myocardial infarct size in man. , 1984, Circulation.

[34]  W. O’Neill,et al.  Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. , 1991, Annals of internal medicine.

[35]  A. Maseri,et al.  Age-Related Increase in Mortality among Patients with First Myocardial Infarctions Treated with Thrombolysis , 1993 .

[36]  P. Shah,et al.  Angiographic validation of bedside markers of reperfusion. , 1993, Journal of the American College of Cardiology.

[37]  B. McNeil,et al.  Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project. , 1996, JAMA.

[38]  R. Robinson,et al.  Depression following Myocardial Infarction , 1992, International journal of psychiatry in medicine.

[39]  E. Braunwald,et al.  Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. , 1990, Journal of the American College of Cardiology.

[40]  H. White,et al.  Significance of diabetes mellitus in patients with acute myocardial infraction receiving thrombolytic theraphy , 1993 .

[41]  R. Califf,et al.  Scorecard Cardiovascular Medicine: Its Impact and Future Directions , 1994, Annals of Internal Medicine.

[42]  E. Topol,et al.  Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. , 1987, The American journal of cardiology.

[43]  K. Lee,et al.  Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. , 1990, The American journal of cardiology.

[44]  E. Braunwald,et al.  Comparison of Clinical Outcomes for Women and Men after Acute Myocardial Infarction , 1994, Annals of Internal Medicine.

[45]  M. Simoons,et al.  Value of admission electrocardiogram in predicting outcome of thrombolytic therapy in acute myocardial infarction. A randomized trial conducted by The Netherlands Interuniversity Cardiology Institute. , 1987, The American journal of cardiology.

[46]  K. Wegscheider,et al.  Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. , 1994, Journal of the American College of Cardiology.

[47]  J. Boissel,et al.  Importance of quantitative analysis of ventricular arrhythmias for predicting the prognosis in low-risk postmyocardial infarction patients. European Infarction Study Group. , 1990, European heart journal.

[48]  R. Califf,et al.  Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. , 1993, Journal of the American College of Cardiology.

[49]  R. Califf,et al.  Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? , 1996, American heart journal.

[50]  J. Alpert,et al.  Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. , 1990, American heart journal.

[51]  K. Lee,et al.  Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. , 1995, The American journal of cardiology.

[52]  C. Viscoli,et al.  Differences between women and men in survival after myocardial infarction. Biology or methodology , 1990 .

[53]  R. Califf,et al.  Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. , 1995, The American journal of cardiology.

[54]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[55]  G. Tognoni,et al.  The GISSI Study: further analysis. Italian Group for the Study of Streptokinase in Myocardial Infarction (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico, GISSI). , 1987, Circulation.

[56]  A. Jaffe,et al.  Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. , 1988, Journal of the American College of Cardiology.